HCPCS J2506: Pegfilgrastim Injection, 0.5 mg

HCPCS Level II code J2506 denotes a 0.5 mg unit of pegfilgrastim (excludes biosimilar), a long-acting granulocyte colony-stimulating factor used to prevent chemotherapy-induced neutropenia. This code is nationally significant because pegfilgrastim is commonly used in oncology care to reduce febrile neutropenia, shorten hospital stays, and support continuation of planned chemotherapy dosing. Accurate coding for biologic injectables affects claims processing, medical necessity review, and drug utilization monitoring across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for pegfilgrastim, typical sites of service for administration, and the implications of using a non-biosimilar product distinct from biosimilars. The publication summarizes reimbursement and billing benchmarks, common payer policies and coverage considerations, and relevant coding nuances for dose-based HCPCS drug units. Where input data is not provided, the report notes that specific fields are not available.

This summary provides clinicians, billing professionals, and policy analysts with concise reference information to support correct use of HCPCS Level II code J2506 in outpatient oncology and infusion settings.

Billing Code Overview

HCPCS Level II code J2506 represents injection, pegfilgrastim, excludes biosimilar, 0.5 mg. This HCPCS drug code denotes a dose-based billing unit for the biologic pegfilgrastim, a granulocyte colony-stimulating factor (G-CSF) used to reduce the incidence of infection in patients receiving myelosuppressive chemotherapy.

Service type: Pharmacologic injectable therapy

Typical site of service: Outpatient infusion or clinic administration, including oncology clinics, hospital outpatient departments, and ambulatory infusion centers. Data not available in the input.

Clinical Context

A typical patient is an adult receiving myelosuppressive chemotherapy for a solid tumor or hematologic malignancy and is at risk for chemotherapy-induced neutropenia. The patient presents to an oncology infusion center for same-day supportive care following chemotherapy administration. The clinician orders J2506 (pegfilgrastim, excludes biosimilar, 0.5 mg) as a single subcutaneous or intramuscular injection to reduce the duration of neutropenia and the incidence of febrile neutropenia. The clinical workflow includes verification of chemotherapy regimen and timing, allergy reconciliation, vital signs, informed consent for supportive biologic therapy, preparation of the dose by pharmacy or clinician per institutional policy, administration in the clinic (or provision and instruction for on-body injector), observation for immediate adverse reactions (typically 15–30 minutes), documentation of lot number and site of injection, and billing the product under J2506 with any applicable modifier(s) to reflect circumstances of service, payment, or clinical complexity.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	When a portion of a multi-dose vial or syringe is discarded and documentation supports billing for the administered portion while reporting discarded portion per payer policy.

Taxonomy Code	Specialty	Notes
207Q00000X	Hematology & Oncology	Oncologists prescribing and overseeing pegfilgrastim therapy.
208000000X	Medical Oncology	Specialists managing chemotherapy regimens and supportive care.
363A00000X	Infusion Nurse	Nurses who prepare and administer subcutaneous injections in infusion centers.
174400000X	Nurse Practitioner	Advanced practice clinicians who may order and administer supportive oncology medications.
2086S0123X	Pharmacist	Clinical pharmacists who prepare, verify dosing, and document biologic drug preparation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D70.9`	Agranulocytosis, unspecified	Neutropenia requiring prophylactic colony-stimulating factor therapy.
`D71`	Functional disorders of polymorphonuclear neutrophils	Conditions with neutrophil dysfunction where growth factors may be considered.
`C80.1`	Malignant (primary) neoplasm, unspecified	Solid tumor patients receiving myelosuppressive chemotherapy.
`C81.99`	Hodgkin lymphoma, unspecified site, unspecified stage	Hematologic malignancy treatment settings where pegfilgrastim is used to prevent neutropenia.
`C85.9`	Non-Hodgkin lymphoma, unspecified	Hematologic malignancies commonly treated with regimens requiring neutropenia prophylaxis.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Commonly billed for the professional service of administering a subcutaneous injection when payers require a CPT-level administration code in addition to the J-code for the drug.
`96413`	Chemotherapy administration, intravenous infusion technique; extra single drug infusion (each additional drug)	May be billed in the same treatment episode for chemotherapy infusion services that precede pegfilgrastim administration when clinically appropriate.
`99070`	Supplies and materials (eg, syringes, needles, drug administration supplies)	Used to bill for non-covered, billable supplies associated with preparation and administration in some payer scenarios.
`99212`	Office or other outpatient visit for the evaluation and management of an established patient, low complexity	May be billed when an E/M visit is performed on the same day as `J2506` and meets documentation requirements (use modifier `25` when appropriate).
`96360`	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	Included as an example of supportive care services that may occur the same day; bill only when performed and documented.

OpenPayer

Summary & Overview